LEI:
549300Q7EXQQH6KF7Z84
15 November
2024
RTW Biotech Opportunities
Ltd
CORXEL Announces Acceptance of NDA for
Aficamten
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased
to note the announcement by portfolio company, CORXEL Pharmaceuticals ("CORXEL"), of
the acceptance by China's National Medical Products Administration
(NMPA) of the New Drug Application (NDA) for Aficamten for the
treatment of obstructive hypertrophic cardiomyopathy
(HCM).
Aficamten is an investigational,
next-in-class selective small molecule cardiac myosin inhibitor. It
received Breakthrough Therapy Designation for the treatment of
symptomatic obstructive HCM from the U.S. Food & Drug
Administration (FDA) as well as the NMPA. HCM is a
genetic heart disease in which the heart muscle becomes abnormally
thick and ultimately limits the heart's pumping function. It is the
most common inherited cardiovascular disorder, with approximately
132,000-330,000 patients diagnosed in China and an estimated
748,000-1,870,000 who remain undiagnosed.
CORXEL, formerly called Ji Xing
Pharmaceuticals, is a leading biotech company committed to bringing
innovative science and medicines to underserved patients with
cardiometabolic diseases. CORXEL was founded and launched by RTW
Investments (the "Investment
Manager") in 2019. In July 2020, CORXEL entered into a
license and collaboration agreement with Cytokinetics, a late-stage
biopharmaceutical company headquartered in California, pursuant to
which Cytokinetics granted CORXEL an exclusive license to develop
and commercialise Aficamten in Greater China.
Roderick Wong,
Managing Partner and CIO at the
Investment Manager commented on the news, "We are thrilled to see
the acceptance of the NDA for Aficamten, a significant milestone
for CORXEL and a testament to its commitment to bringing innovative
therapies to patients with cardiometabolic diseases. This
achievement underscores the dedication and hard work of the CORXEL
team. We look forward to continuing to support them in their
efforts to deliver groundbreaking treatments that address unmet
medical needs and improve patient outcomes."
The full text of the announcement can be
accessed
here.
For Further
Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Cadarn Capital (PR & Communications / Distribution &
IR Partner)
Lucy Clark (PR)
David Harris
(Distribution)
|
+44
79 8418 4461
Lucy@cadarncapital.com
+44
73 6888 3211
david@cadarncapital.com
|
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield
|
+44
20 7260 1000
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44 14 8170 3100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********